Propanc Biopharma (PPCB) Stock: Company Secures $100M Crypto Treasury Deal

TLDR

• Propanc Biopharma secured up to $100 million from crypto-focused family office Hexstone Capital through a convertible preferred stock deal
• The company received an initial $1 million investment with up to $99 million available over the next 12 months
• Funds will be used to build a digital asset treasury and advance cancer therapy PRP toward first-in-human trials in second half of 2026
• PPCB shares dropped 10.5% on Nasdaq following the announcement and are down 46.7% over the past month
• The company plans to target undervalued digital asset treasury companies trading below their market cap to net asset value ratio

Propanc Biopharma announced Monday it has secured up to $100 million in funding from Hexstone Capital. The Australia-based biotech company plans to use the money to launch a crypto treasury while continuing development of its cancer treatment.

The deal is structured as a private placement through convertible preferred stock. Propanc received an initial $1 million investment upfront.

The remaining $99 million will be available over the next 12 months. Hexstone Capital is a family office that invests in various crypto treasury companies.

The proceeds will serve two purposes for Propanc. First, the company will build a digital asset treasury. Second, it will accelerate development of PRP, its lead cancer therapy product.

PRP is a proenzyme-based oncology treatment. The company aims to begin first-in-human trials in the second half of 2026.

CEO James Nathanielsz described the move as entering a “transformative phase” for the company. He said the crypto treasury would strengthen the balance sheet and advance the proenzyme platform.

Nathanielsz noted the therapy could target patients with metastatic cancer from solid tumors. He also mentioned potential applications for several chronic diseases based on the mechanism of action.

Digital Asset Portfolio Plans

Propanc did not specify which digital assets it plans to purchase for its treasury. However, Hexstone’s clients have invested in Bitcoin, Ether, Solana, and Injective, among others.

Earlier this month, Propanc disclosed plans for a strategic initiative. The company wants to acquire undervalued digital asset treasury companies.

The target is DAT companies that trade below their market cap to net asset value. This approach offers potential diversification while continuing cancer research.

The biotech firm joins other companies like Sonnet BioTherapeutics and Sharps Technology. These biotechs have turned to crypto strategies to reignite investor interest.

Market Reaction and Broader Context

Investors did not respond positively to the announcement. PPCB shares fell 10.5% on the Nasdaq on Monday, according to Yahoo Finance data.

The stock’s performance has been rough lately. PPCB shares are now down 46.7% over the last month.

Propanc’s move comes as crypto treasury strategies face headwinds. Bitcoin treasury holding companies have lost momentum in recent months as more firms enter the space.

Strategy, the largest corporate Bitcoin holder, has seen its market cap slide over 43%. The company dropped from $122.1 billion in July to $69.1 billion.

Metaplanet, one of the best-performing stocks on the Tokyo Stock Exchange early this year, fell harder. The company has dropped around 55% since late June.

Some Bitcoin treasury companies have even had to sell BTC holdings to pay outstanding debt. The trend suggests the crypto treasury model faces growing challenges.

Hexstone Capital already has a portfolio of digital asset treasury investments. These include companies holding Bitcoin, Ethereum, Solana, Dogecoin, and Injective.

The agreement provides Propanc with flexibility through its convertible preferred stock structure. The company can draw on funds as needed over the next year to build its digital asset position.

The post Propanc Biopharma (PPCB) Stock: Company Secures $100M Crypto Treasury Deal appeared first on CoinCentral.